Antihemophilic factor, human recombinant is a form of recombinant coagulation Factor VIII used to treat hemophilia A, von Willebrand disease, and Factor XIII deficiency. A medication used in the treatment of some types of bleeding disorders.
- Mechanism
- Curator reviewed
Antihemophilic factor (AHF) is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A (classical hemophilia).
- Primary indication
- The human recombinant antihemophilic factor is indicated for use in adults and children with hemophilia A for the control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency...Curator reviewed · 6 structured indications
- Formula / weight
- C11794H18314N3220O3553S83 · 264725.5 Da
- First approval
- Canada, 2004 · United States, 2000 · European Union, 2016
- Also known as
- Antihemophilic factor (recombinant) · Antihemophilic factor recombinant · Antihemophilic factor, recombinant · Coagulation factor VIII, recombinant · Factor VIII (rDNA)
- Code names
- BAY 14-2222 · BAY 81-8973 · BAY-W-6240
- Brand names
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Antihemophilic factor, human recombinant, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account